Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Verona’s ensifentrine: a potentially revolutionary treatment for COPD

The current standard of care for COPD is at least one or two bronchodilators, sometimes supplemented by an anti-inflammatory inhaled corticosteroid, however, two-thirds of patients on the maximum triple therapy for the condition remain symptomatic. Verona Pharma is developing a possible solution primarily for these severe COPD patients called ensifentrine, which has a novel mechanism of action and combines bronchodilator and anti-inflammatory properties. Verona Pharma is developing a possible solution primarily for these severe COPD patients called ensifentrine, which has a novel mechanism of action and combines bronchodilator and anti-inflammatory properties.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top